A. Text – The United States federal government should buy enough antiretroviral drugs at market price from relevant pharmaceutical companies to distribute to Sub-Saharan Africa. We’ll clarify.
B. Competition – The counterplan competes off of case and politics
C. Solvency –
Generics are still too expensive for most African countries to purchase
Peggy B. Sherman, Assistant Professor of Legal Studies at Georgia State University, and Ellwood F. Oakley, III, Associate Professor of Legal Studies at Georgia State University, 2004
[“Pandemics and Panaceas: The World Trade Organization's Efforts to Balance Pharmaceutical Patents and Access to AIDS Drugs,” American Business Law Journal, 41 Am. Bus. L.J. 353, Winter/Spring, Lexis] Rein
Most African countries have budgets too small and health systems too weak to take advantage of the availability of inexpensive drugs, even at Cipla's discounted rates. 204 Cipla's generic AIDS drugs, despite their significantly lower price, have sold very poorly. Venkat Kamalakar, general manager of international operations for Aurobindo, another Indian generic drug manufacturer, has likewise stated that the "rock-bottom prices" charged by Aurobindo are too expensive for most African countries. 205 Legal debates over compulsory licensing and parallel importing are of minimal use to many African countries too poor to afford anti-AIDS drugs at any price.
A. Text – The United States federal government should buy enough antiretroviral drugs at market price from relevant pharmaceutical companies to distribute to Sub-Saharan Africa. We’ll clarify.
B. Competition – The counterplan competes off of case and politics
C. Solvency –
Generics are still too expensive for most African countries to purchase
Peggy B. Sherman, Assistant Professor of Legal Studies at Georgia State University, and Ellwood F. Oakley, III, Associate Professor of Legal Studies at Georgia State University, 2004
[“Pandemics and Panaceas: The World Trade Organization's Efforts to Balance Pharmaceutical Patents and Access to AIDS Drugs,” American Business Law Journal, 41 Am. Bus. L.J. 353, Winter/Spring, Lexis] Rein
Most African countries have budgets too small and health systems too weak to take advantage of the availability of inexpensive drugs, even at Cipla's discounted rates. 204 Cipla's generic AIDS drugs, despite their significantly lower price, have sold very poorly. Venkat Kamalakar, general manager of international operations for Aurobindo, another Indian generic drug manufacturer, has likewise stated that the "rock-bottom prices" charged by Aurobindo are too expensive for most African countries. 205 Legal debates over compulsory licensing and parallel importing are of minimal use to many African countries too poor to afford anti-AIDS drugs at any price.